X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target lowered by analysts at HC Wainwright from $5.00 to $1.50. They now have a "buy" rating on the stock.
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $4.00. They now have a "buy" rating on the stock.
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference [Yahoo! Finance]
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ... [Yahoo! Finance]